Loading...
XWAR
CRM
Market cap11mUSD
Jul 22, Last price  
0.50PLN
1D
-1.57%
1Q
-8.42%
Jan 2017
-75.96%
IPO
-87.65%
Name

PZ Cormay SA

Chart & Performance

D1W1MN
P/E
P/S
0.51
EPS
Div Yield, %
Shrs. gr., 5y
1.44%
Rev. gr., 5y
3.33%
Revenues
82m
-3.67%
31,085,00038,451,00061,940,00090,027,000105,473,000100,800,000100,111,00045,004,00082,277,00077,585,00069,793,00068,410,00065,290,00084,732,00085,361,00082,225,000
Net income
-4m
L-32.33%
1,420,0002,956,0006,130,00014,008,00015,382,0006,853,000-47,357,000-5,157,000-10,990,000-2,021,000-24,982,000-40,974,000-12,821,0001,635,000-6,644,000-4,496,000
CFO
-3m
L-62.69%
2,203,000-1,582,000-9,747,0002,334,0002,254,000-17,451,0007,928,000-5,271,000-5,167,0001,656,000-1,561,000-4,390,000-161,000-1,469,000-8,709,000-3,249,000

Profile

PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland. It offers testing products for clinical chemistry, hematology, veterinary, urinalysis, and parasitology, as well as rapid test products. The company serves small and medium size clinical laboratories, clinics, and hospitals. It distributes its products to approximately 120 countries. PZ Cormay S.A. was founded in 1985 and is headquartered in Lomianki, Poland.
IPO date
Aug 20, 2008
Employees
222
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
82,225
-3.67%
85,361
0.74%
Cost of revenue
87,426
88,853
Unusual Expense (Income)
NOPBT
(5,201)
(3,492)
NOPBT Margin
Operating Taxes
681
402
Tax Rate
NOPAT
(5,882)
(3,894)
Net income
(4,496)
-32.33%
(6,644)
-506.36%
Dividends
(5)
Dividend yield
0.01%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,279
1,212
Long-term debt
8,549
6,624
Deferred revenue
636
Other long-term liabilities
953
192
Net debt
(244)
(7,163)
Cash flow
Cash from operating activities
(3,249)
(8,709)
CAPEX
(5,634)
(8,435)
Cash from investing activities
5,520
8,969
Cash from financing activities
(19)
(1,337)
FCF
2,599
10,333
Balance
Cash
10,020
14,947
Long term investments
52
52
Excess cash
5,961
10,731
Stockholders' equity
(43,471)
(31,055)
Invested Capital
105,006
96,359
ROIC
ROCE
EV
Common stock shares outstanding
84,205
84,205
Price
0.59
-33.71%
0.89
-22.87%
Market cap
49,513
-33.71%
74,690
-22.87%
EV
49,681
68,023
EBITDA
(1,758)
1,114
EV/EBITDA
61.06
Interest
1,064
936
Interest/NOPBT